Cidara Therapeutics to Participate in Anti-Infectives Panel Discussion at the 2017 Infectious Diseases Summit
July 06 2017 - 8:30AM
Business Wire
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology
company developing novel anti-infectives including immunotherapies,
today announced that Jeffrey Stein, Ph.D., president and chief
executive officer, will be participating in a panel discussion at
the 2017 Infectious Diseases Summit being held July 13-14 in
Baltimore, Maryland. The interactive panel will be part of the
Summit’s 14th Anti-Infectives Partnering & Deal-Making
Conference that will focus on the types and availability of
economic incentives to spur innovation and development of therapies
to address rapidly emerging global health threats. Details of the
panel discussion are as follows:
Session Name: Pushing and Pulling- What Incentives Help
Spark Innovation in Antibiotic Drug Discovery and
Development?Date and time: Friday, July 14, 2017 at 8:30
a.m. Eastern Time (ET)Location: Royal Sonesta, Baltimore
Dr. Stein is also the chairman of the Antimicrobials Working
Group (AWG), an industry-led coalition of emerging antimicrobial
companies that aims to provide a collective voice in policy and
regulatory solutions. He is widely recognized within the industry
for his expertise in the discovery and development of
antimicrobials.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on
developing new anti-infectives that have the potential to transform
the standard of care and save or improve patients’ lives. The
company is currently advancing its novel echinocandin antifungal,
CD101 IV, through Phase 2 and developing CD201, its bispecific
antibiotic immunotherapy, for the treatment of multi-drug resistant
Gram-negative bacterial infections. CD101 IV has improved
pharmacokinetics compared to existing echinocandins and has the
potential for expanded utility across patient settings. CD101 IV is
the only once-weekly product candidate in development for the
treatment and prevention of life-threatening invasive fungal
infections. CD201 is the first drug candidate selected from
Cidara’s novel Cloudbreak™ platform, the first immunotherapy
discovery platform designed specifically to create compounds that
direct a patient’s immune cells to attack and eliminate bacterial,
fungal or viral pathogens. Cidara has received a grant for up to
$6.9 million from CARB-X (Combating Antibiotic Resistant Bacteria
Accelerator) to advance the development of CD201. Cidara is
headquartered in San Diego, California. For more information,
please visit www.cidara.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effectiveness, safety, and other attributes of CD101 and CD201
and other potential product candidates, including the potential for
these compounds to successfully treat or prevent infections,
including those caused by resistant pathogens, and potentially
transform the way infectious diseases are treated, and the
potential for the Cloudbreak platform to result in future drug
candidates. Risks that contribute to the uncertain nature of the
forward-looking statements include: the success and timing of
Cidara’s preclinical studies and clinical trials; regulatory
developments in the United States and foreign countries; changes in
Cidara’s plans to develop and commercialize its product candidates;
Cidara’s ability to obtain additional financing; Cidara’s ability
to obtain and maintain intellectual property protection for its
product candidates; and the loss of key scientific or management
personnel. These and other risks and uncertainties are described
more fully in Cidara’s Form 10-Q most recently filed with the
United States Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Cidara undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170706005160/en/
Cidara Therapeutics, Inc.INVESTOR CONTACT:Westwicke
Partners, LLCRobert H. Uhl, 858-356-5932Managing
Directorrobert.uhl@westwicke.comorMEDIA CONTACT:Sam Brown
Inc.Christy Curran, 615-414-8668ChristyCurran@sambrown.com
Cidara Therapeutics (NASDAQ:CDTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cidara Therapeutics (NASDAQ:CDTX)
Historical Stock Chart
From Apr 2023 to Apr 2024